<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Van de Werf, Frans</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TECOS Finds Sitagliptin Does Not Increase Heart Failure Risk</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-21 10:14:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">TECOS was a large randomized placebo-controlled trial in patients with type 2 diabetes mellitus and cardiovascular disease, conducted to demonstrate the noninferiority of sitagliptin as compared with placebo in the risk of cardiovascular events. A prespecified secondary analysis found no impact of sitagliptin on heart failure hospitalization or related events.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>